secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2026-08-13T20:45:32+00:00
Accession:  0001493152-26-037840
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics Q2 2026 net loss narrows to $4.2M; FDA agrees on CLD-401 path
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders: $4.2M ($2.94/share) vs $5.7M ($31.75/share) in Q2 2025, adjusted for 1-for-16 reverse split.
- G&A expenses cut 48% to $1.6M from $3.1M; R&D flat at $2.6M.
- Cash and restricted cash $4.3M at June 30, 2026 vs $5.8M at Dec 31, 2025.
- FDA pre-IND feedback for CLD-401 supports first-in-human study; first patient dosing targeted Q1 2027.
- Added Corsee Sanders, Ph.D. (ex-Genentech/Roche, Celgene) to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/0001493152-26-037840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer